Upstream Bio (UPB) Share-based Compensation (2023 - 2026)
Upstream Bio (UPB) posted quarterly Share-based Compensation of $43.4 million for Q1 2026, up 1547.06% year-over-year from $2.6 million in Q1 2025, and up 654.56% quarter-over-quarter from -$7.8 million in Q4 2025.
Upstream Bio (UPB) Share-based Compensation (2023 - 2026) Analysis & Trends
Upstream Bio's Share-based Compensation history runs 4 years deep, the most recent figure standing at $43.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 1547.06% year-over-year to $43.4 million; the TTM figure through Mar 2026 stood at $43.4 million (up 442.77% YoY), while the FY2025 annual figure was $21.4 million, up 37.18% from the prior year.
- Share-based Compensation for Q1 2026 stood at $43.4 million, up from -$7.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $43.4 million in Q1 2026, with the low at -$7.8 million in Q4 2025.
- The 4-year median for Share-based Compensation is $1.9 million (2024), against an average of $8.5 million.
- Peak annual rise in Share-based Compensation reached 1628.05% in 2025, while the deepest fall reached 475.17% in 2025.
- Upstream Bio's Share-based Compensation stood at $711000.0 in 2023, then soared by 193.39% to $2.1 million in 2024, then plunged by 475.17% to -$7.8 million in 2025, then soared by 654.56% to $43.4 million in 2026.
- Business Quant data shows UPB's Share-based Compensation at $43.4 million in Q1 2026, -$7.8 million in Q4 2025, and $23.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 39.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.70 Mn |
| Jun 30, 2026 | 39.70 Mn |
| Mar 31, 2026 | 43.40 Mn |
| Mar 31, 2026 | 43.40 Mn |
| Dec 31, 2025 | -7.83 Mn |
| Dec 31, 2025 | -7.83 Mn |
| Sep 30, 2025 | 23.00 Mn |
| Sep 30, 2025 | 23.00 Mn |
| Jun 30, 2025 | 24.40 Mn |
| Jun 30, 2025 | 24.40 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 643,000.00 |
| Mar 31, 2024 | 643,000.00 |